A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News HighlightsAerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Pro... Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamet... Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s...
Aug 14, 3:20 PM ET
52 - WEEK LOW/HIGH